Featured Company /
Relevium Technologies Inc.
The health and wellness market is one that is broad and deep, covering hundreds of thousands of products that made up a $3.7 trillion worldwide industry in 2015. With personal health and wellbeing a strengthening trend across the planet, the Global Wellness Institute estimates that market size was achieved through 10.2% growth across 2013-2015, making it one of the fastest growing industries worldwide.
There are leading players in the market, considering the scope of portfolios for companies like Estee Lauder (NYSE:EL) and Coty (NYSE:COTY), but there is plenty of room for market share for smaller companies following the same model of consolidating brands, like the plan of Relevium Technologies (TSX-Venture:RLV). The Montreal, Canada-based company is focused on acquiring profitable businesses, products and technologies in the health and wellness sector, with a particular interest in e-commerce sales channels.
This strategy is underscored by the fact that less than 10% of sales in the health and wellness market are generated through online sales. In today’s highly digitized and mobile world, expectations are for online sales to grow 17% annually, aligning Relevium to try and capital on two large growth segments.
The company sets its sights on acquisition targets that are generating between $2 million and $20 million annually that can be acquired at favorable multiples in the area of 4-times earnings before interest and taxes (EBIT). In June, Relevium executed on this model, completing the acquisition of nutraceutical product company BioGanix for US$5.8 million (3.7X EBIT). The buyout brought BioGanix’s website properties, formulations, inventory and product pipeline under the Relevium umbrella.
BioGanix has a strong e-commerce presence, generating 90% of its trailing-twelve-month C$5 million in revenue and C$1.3 in trailing-twelve-month cash flow from Amazon.
Founded to produce superior products in the U.S. using only the best ingredients to overcome shortcomings in popular nutraceutical products that failed to meet claims or even contain the listed amounts of active ingredients, BioGanix has quickly gained market traction and a strong feedback profile (99% positive) on Amazon. Products include the top selling product on Amazon in the “Carb Blocker” Category and others that have broken into the Top 200 in their respective category ahead of tens of thousands of competitors.
The proof is in the sales, which have grown from zero at launch in 2013 to just over $5.0 million in 2016, while net income has risen from zero to nearly $2.0 million.
During the first 50 days of operations as part of Relevium, sales continued to improve, climbing to approximately C$700,000, an increase of 52% from the year prior period, as the integration of new management works with existing Relevium management to optimize operations.
Relevium says that it has a pipeline of potential acquisitions all falling within their requisite sales and EBIT parameters, with an aggregate of revenue in excess of C$80 million and EBIT of C$24 million.
As the seasoned management team makes decisions on new acquisitions – for which it is targeting one every six months – Relevium is working to grow existing sales and add new products, both through BioGanix’s pipeline and through a partnership struck in May with Hempco Food and Fiber (TSX-Venture:HEMP), an established provider of premier hemp seed foods for more than 15 years. In this partnership, the two companies are collaborating to develop a hemp-based nutraceutical and nutritional products line. Per the pact, Relevium has exclusive distribution rights for any future products through its portfolio of brands via popular and global e-commerce platforms such as Amazon and Jet.com.
Elsewhere, Relevium made its first move into big data and artificial intelligence, engaging Montreal-based agileDSS as a data architect for the purpose of developing a consumer trend recommendation engine, a solution for optimizing and automating the product development cycle. The plan is to transition away from human interpretation of data and use artificial intelligence to evaluate demand for new products and the best demographics for product launches ahead of developing trends.
While many may think of Silicon Valley in California as the global hotbed for tech, Montreal is quickly emerging as a global hub for data analytics and artificial intelligence. This is evidenced by investments by Google (NASDAQ:GOOGL) to open an AI lab in the city, Microsoft (NASDAQ:MSFT) saying it is buying Montreal-based AI firm Maluuba and Montreal-based startup incubator Element AI announcing a whopping $102 million Series A round.
The phrase “right place, right time” may be often overused, but such is not the case here with Relevium looking to tap local talent to build next-generation technology to make the most informed decisions on what consumers want and where by plugging into the power of big data and AI.
Relevium remains highly overlooked by most of the investment community, but not by insiders who have plenty of skin in the game. BioGanix founder Albertus Petrus Engelbrecht rolled his profitable company into Relevium for cash ($2.6M up front, $675K in 12 months), $675K in stock up front and a $2.1M convertible note, demonstrating his belief in the future of the company. Considering the conversion price for Engelbrecht’s note is at C$0.1396, he is obviously optimistic that shares are going to maintain current levels (C$0.155) and appreciate going forward.
Overall, insiders hold 33% of the 65 million shares outstanding, leaving a public float of approximately 29.9 million, enough shares to keep the stock liquid, but few enough to mean that even slight buying pressure can move shares quickly.
Relevium is aggressive in executing on a compelling business model targeting large and growing market opportunities, with the new AI initiatives particularly compelling with its implications to make succinct and prescient decisions in product development and launch. When taking a closer look at health and wellness, investors should take note that there is a quickly rising appreciation for self-care and holistic approaches, with consumers increasingly looking to e-commerce to purchase products. These are exactly the areas that Relevium, with its sub $10M market cap, are squarely pointed for growth, giving them the opportunity to grow long legs and garner market attention in the near term.
Corporate Snapshot:
Relevium Technologies Inc.
Stock Symbol:
CA
Stock Exchange:
TSX-Venture
Sector:
Healthcare
52 Week High:
$0.2200
52 Week Low:
$0.0450
Current Stock Quote / Chart / News: Click here
Information as of
October 11, 2017
The health and wellness market is one that is broad and deep, covering hundreds of thousands of products that made up a $3.7 trillion worldwide industry in 2015. With personal health and wellbeing a strengthening trend across the planet, the Global Wellness Institute estimates that market size was achieved through 10.2% growth across 2013-2015, making it one of the fastest growing industries worldwide.
There are leading players in the market, considering the scope of portfolios for companies like Estee Lauder (NYSE:EL) and Coty (NYSE:COTY), but there is plenty of room for market share for smaller companies following the same model of consolidating brands, like the plan of Relevium Technologies (TSX-Venture:RLV). The Montreal, Canada-based company is focused on acquiring profitable businesses, products and technologies in the health and wellness sector, with a particular interest in e-commerce sales channels.
This strategy is underscored by the fact that less than 10% of sales in the health and wellness market are generated through online sales. In today’s highly digitized and mobile world, expectations are for online sales to grow 17% annually, aligning Relevium to try and capital on two large growth segments.
The company sets its sights on acquisition targets that are generating between $2 million and $20 million annually that can be acquired at favorable multiples in the area of 4-times earnings before interest and taxes (EBIT). In June, Relevium executed on this model, completing the acquisition of nutraceutical product company BioGanix for US$5.8 million (3.7X EBIT). The buyout brought BioGanix’s website properties, formulations, inventory and product pipeline under the Relevium umbrella.
BioGanix has a strong e-commerce presence, generating 90% of its trailing-twelve-month C$5 million in revenue and C$1.3 in trailing-twelve-month cash flow from Amazon.
Founded to produce superior products in the U.S. using only the best ingredients to overcome shortcomings in popular nutraceutical products that failed to meet claims or even contain the listed amounts of active ingredients, BioGanix has quickly gained market traction and a strong feedback profile (99% positive) on Amazon. Products include the top selling product on Amazon in the “Carb Blocker” Category and others that have broken into the Top 200 in their respective category ahead of tens of thousands of competitors.
The proof is in the sales, which have grown from zero at launch in 2013 to just over $5.0 million in 2016, while net income has risen from zero to nearly $2.0 million.
During the first 50 days of operations as part of Relevium, sales continued to improve, climbing to approximately C$700,000, an increase of 52% from the year prior period, as the integration of new management works with existing Relevium management to optimize operations.
Relevium says that it has a pipeline of potential acquisitions all falling within their requisite sales and EBIT parameters, with an aggregate of revenue in excess of C$80 million and EBIT of C$24 million.
As the seasoned management team makes decisions on new acquisitions – for which it is targeting one every six months – Relevium is working to grow existing sales and add new products, both through BioGanix’s pipeline and through a partnership struck in May with Hempco Food and Fiber (TSX-Venture:HEMP), an established provider of premier hemp seed foods for more than 15 years. In this partnership, the two companies are collaborating to develop a hemp-based nutraceutical and nutritional products line. Per the pact, Relevium has exclusive distribution rights for any future products through its portfolio of brands via popular and global e-commerce platforms such as Amazon and Jet.com.
Elsewhere, Relevium made its first move into big data and artificial intelligence, engaging Montreal-based agileDSS as a data architect for the purpose of developing a consumer trend recommendation engine, a solution for optimizing and automating the product development cycle. The plan is to transition away from human interpretation of data and use artificial intelligence to evaluate demand for new products and the best demographics for product launches ahead of developing trends.
While many may think of Silicon Valley in California as the global hotbed for tech, Montreal is quickly emerging as a global hub for data analytics and artificial intelligence. This is evidenced by investments by Google (NASDAQ:GOOGL) to open an AI lab in the city, Microsoft (NASDAQ:MSFT) saying it is buying Montreal-based AI firm Maluuba and Montreal-based startup incubator Element AI announcing a whopping $102 million Series A round.
The phrase “right place, right time” may be often overused, but such is not the case here with Relevium looking to tap local talent to build next-generation technology to make the most informed decisions on what consumers want and where by plugging into the power of big data and AI.
Relevium remains highly overlooked by most of the investment community, but not by insiders who have plenty of skin in the game. BioGanix founder Albertus Petrus Engelbrecht rolled his profitable company into Relevium for cash ($2.6M up front, $675K in 12 months), $675K in stock up front and a $2.1M convertible note, demonstrating his belief in the future of the company. Considering the conversion price for Engelbrecht’s note is at C$0.1396, he is obviously optimistic that shares are going to maintain current levels (C$0.155) and appreciate going forward.
Overall, insiders hold 33% of the 65 million shares outstanding, leaving a public float of approximately 29.9 million, enough shares to keep the stock liquid, but few enough to mean that even slight buying pressure can move shares quickly.
Relevium is aggressive in executing on a compelling business model targeting large and growing market opportunities, with the new AI initiatives particularly compelling with its implications to make succinct and prescient decisions in product development and launch. When taking a closer look at health and wellness, investors should take note that there is a quickly rising appreciation for self-care and holistic approaches, with consumers increasingly looking to e-commerce to purchase products. These are exactly the areas that Relevium, with its sub $10M market cap, are squarely pointed for growth, giving them the opportunity to grow long legs and garner market attention in the near term.
Forward Looking Statements
This report includes forward-looking statements that reflect current expectations about its future results, performance, prospects and opportunities. Relevium Technologies Inc. has tried to identify these forward-looking statements by using words and phrases such as "may," "will," "expects," "anticipates," "believes," "intends," "estimates," "plan," "should," "typical," "preliminary," "we are confident" or similar expressions. These forward-looking statements are based on information currently available and are subject to a number of risks, uncertainties and other factors that could cause Relevium Technologies Inc.'s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These risks, uncertainties and other factors include, without limitation, the Company's growth expectations and ongoing funding requirements, and specifically, the Company's growth prospects with scalable customers, and those outlined above. Other risks include the Company's limited operating history, the Company's history of operating losses, consumers' acceptance, the Company's use of licensed technologies, risk of increased competition, the potential need for additional financing, the terms and conditions of any financing that is consummated, the limited trading market for the Company's securities, the possible volatility of the Company's stock price, the concentration of ownership, and the potential fluctuation in the Company's operating results.
Disclaimer
AllPennyStocks.com feature stock reports are intended to be stock ideas, NOT recommendations. Please do your own research before investing. It is crucial that you at least look at current SEC filings and read the latest press releases. Information contained in this report was extracted from current documents filed with the SEC, the company web site and other publicly available sources deemed reliable. For more information see our disclaimer section, a link of which can be found on our web site. This document contains forward-looking statements, particularly as related to the business plans of the Company, within the meaning of Section 27A of the Securities Act of 1933 and Sections 21E of the Securities Exchange Act of 1934, and are subject to the safe harbor created by these sections. Actual results may differ materially from the Company's expectations and estimates. This is an advertisement for Relevium Technologies Inc. The purpose of this advertisement, like any advertising, is to provide coverage and awareness for the company. The information provided in this advertisement is not intended for distribution to, or use by, any person or entity in any jurisdiction or country where such distribution or use would be contrary to law or regulation or which would subject us to any registration requirement within such jurisdiction or country.
© 1999-2024AllPennyStocks.com Media, Inc. All rights reserved. AllPennyStocks.com is not a Registered Broker/Dealer or Financial Advisor, nor do we hold ourselves out to be. All materials presented on our web site and individual reports released to the public through this web site, e-mail or any other means of transmission are not to be regarded as investment advice and are only for informative purposes. Before making a purchase or sale of any securities featured on our web site or mentioned in our reports, we strongly encourage and recommend consultation with a registered securities representative. This is not to be construed as a solicitation or recommendation to buy or sell securities. As with any stock, companies we select to profile involve a degree of investment risk and volatility. Particularly Small-Caps and OTC-BB stocks. All investors are cautioned that they may lose all or a portion of their investment if they decide to make a purchase in any of our profiled companies. Past performance of our profiled stocks is not indicative of future results. The accuracy or completeness of the information on our web site or within our reports is only as reliable as the sources they were obtained from. The profile and opinions expressed herein are expressed as of the date the profile is posted on site and are subject to change without notice. No investor should assume that reliance on the views; opinions or recommendations contained herein will produce profitable results. AllPennyStocks.com may hold positions in securities mentioned herein, and may make purchases or sales in such securities featured on our web site or within our reports. In order to be in full compliance with the Securities Act of 1933, Section 17(b), AllPennyStocks.com will disclose in its disclaimer, what, if any compensation was received for our efforts in researching, presenting and disseminating this information to our subscriber database and featuring the report on the AllPennyStocks.com web site.
AllPennyStocks.com has been compensated two thousand five hundred dollars from a third-party, Frontier Consulting, Ltd. for its efforts in presenting the RLV profile on its web site and distributing it to its database of subscribers as well as other services. AllPennyStocks.com may decide to purchase or sell shares on a voluntary basis in the open market before, during or after the profiling period of this report. Information presented on our web site and within our reports contain "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements." Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "expects", "will," "anticipates," "estimates, "believes," or that by statements indicating certain actions "may," "could," or "might" occur.
THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SMALL CAP SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK.